Efficacy and safety of sulbactam–durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii–calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK)-Reference-Cited by-同舟云学术

Efficacy and safety of sulbactam–durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii–calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK)

Published:2023-09 Issue:9 Volume:23 Page:1072-1084
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Kaye Keith S,Shorr Andrew F,Wunderink Richard G,Du Bin,Poirier Gabrielle E,Rana Khurram,Miller Alita,Lewis Drew,O'Donnell John,Chen Lan,Reinhart Harald,Srinivasan Subasree,Isaacs Robin,Altarac David

Publisher

Elsevier BV

Subject

Infectious Diseases

Reference30 articles.

1. Epidemiology and outcomes associated with carbapenem-resistant Acinetobacter baumannii and carbapenem-resistant Pseudomonas aeruginosa: a retrospective cohort study;Vivo;BMC Infect Dis,2022

2. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis;Lancet,2022

3. Adverse clinical outcomes associated with carbapenem-resistant Acinetobacter (CRA) infections: a systematic review and meta-analysis;Ling;JAC Antimicrob Resist,2021

4. Mortality, length of stay, and healthcare costs associated with multidrug-resistant bacterial infections among elderly hospitalized patients in the United States;Nelson;Clin Infect Dis,2022

5. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European Society of Intensive Care Medicine);Paul;Clin Microbiol Infect,2022

Cited by 76 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A comprehensive review of small molecule drugs approved by the FDA in 2023: Advances and prospects;European Journal of Medicinal Chemistry;2024-10

2. Sulbactam-durlobactam for the treatment of Acinetobacter baumannii-calcoaceticus complex;Expert Review of Anti-infective Therapy;2024-09-08

3. Molecular epidemiology, microbiological features and infection control strategies for carbapenem-resistant Acinetobacter baumannii in a German burn and plastic surgery center (2020–2022);Antimicrobial Resistance & Infection Control;2024-09-06

4. Acinetobacter spp. in neonatal sepsis: an urgent global threat;Frontiers in Antibiotics;2024-09-03

5. Ampicillin–Sulbactam for Carbapenem-Susceptible Acinetobacter baumannii Pneumonia: A Case for High-Dose, Continuous Infusion Dosing Strategy in the Trauma ICU;Surgical Infections;2024-09-01